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Abstract
Evidence from genetic association and twin studies indicates that susceptibility to tuberculosis (TB) is under genetic control.
One gene implicated in susceptibility to TB is that encoding interleukin-10 (IL10). In a group of 2010 Ghanaian patients with
pulmonary TB and 2346 healthy controls exposed to Mycobacterium tuberculosis, among them 129 individuals lacking a
tuberculin skin test (PPD) response, we genotyped four IL10 promoter variants at positions 22849 , 21082 , 2819 , and
2592 and reconstructed the haplotypes. The IL10 low-producer haplotype 22849A/21082A/2819C/2592C, compared to
the high-producer haplotype 22849G/21082G/2819C/2592C, occurred less frequent among PPD-negative controls than
among cases (OR 2.15, CI 1.3–3.6) and PPD-positive controls (OR 2.09, CI 1.2–3.5). Lower IL-10 plasma levels in homozygous
22849A/21082A/2819C/2592C carriers, compared to homozygous 22849G/21082G/2819C/2592C carriers, were
confirmed by a IL-10 ELISA (p=0.016). Although we did not observe differences between the TB patients and all controls,
our results provide evidence that a group of individuals exposed to M. tuberculosis transmission is genetically distinct from
healthy PPD positives and TB cases. In these PPD-negative individuals, higher IL-10 production appears to reflect IL-10-
dependent suppression of adaptive immune responses and sustained long-term specific anergy.
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Introduction
Innate and adaptive defense mechanisms contribute to anti-
MycobacteriuM. tuberculosis immunity. The view that successful
infection control mostly depends on adaptive responses reflects
observations made with the intradermal application of tuberculin
(purified protein derivative; PPD). Most contacts of tuberculosis
(TB) patients develop a delayed-type hypersensitivity reaction to
tuberculin and are, if remaining healthy, considered protected
from active TB. As the skin papule indicating PPD positivity
contains reactive T lymphocytes, protection is believed to result
from acquired T-cell-mediated immunity. PPD negativity can
result from either lack of previous exposure, anergy due to
overwhelming TB, or from any form of immunosuppression. In
addition, antigen-specific tuberculin anergy in patients with
pulmonary TB in the course of the disease and persisting after
successful treatment has been reported [1]. PPD negativity may
also indicate innate immunity after exposure without induction of
adaptive mechanisms. Taken together, three scenarios are
conceivable after M. tuberculosis infection. After uptake of the
pathogen by alveolar macrophages, i) the pathogen may be
destroyed in a first line of defence without inducing adaptive T-cell
immune responses (PPD negativity), or ii) infection establishes and
adaptive T-cell responses result in containment of bacteria (PPD
positivity), or iii) innate and adaptive immune responses fail,
allowing for outgrowth and spread of bacteria (disease). A firm
molecular basis of the three scenarios remains to be defined.
A substantial influence of the human genetic constitution on TB
susceptibility has been shown [2]. Early reports of familial
hereditary and clustered disease, data from accidental application
of virulent M. tuberculosis during a BCG vaccination campaign [3],
first outbreaks in indigenous populations without prior experience
of TB and outbreaks in closed environments [4–6], higher
concordance of TB in monozygotic than in dizygotic twins [7–
9], and family linkage and case-control association studies [10–12]
underline that host genetic factors contribute to the outcome of M.
tuberculosis infection. Furthermore, ethnic differences in TB
susceptibility argue for a predisposing component of the human
genetic make-up in disease susceptibility [6,13].
One of the genes implicated in TB susceptibility in several
studies is that encoding interleukin 10 (IL-10; OMIM 124092).
Association studies performed so far of IL10 variants in TB have
yielded ambiguous results. Heterozygosity of the 21082 variant
was associated with an increased TB risk in Cambodia [14], and
the 2592 C allele with a decreased TB risk in Korea [15]. In
a population from Hongkong, the 21082G/2819C/2592C
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5420haplotype was weakly associated with relapses of pulmonary TB
and with extrapulmonary TB [16]. No influence of IL10 promoter
variants on the occurence of TB in HIV-negative individuals was
observed in Malawi and Spain [17,18]. In a recent study from
Turky, the the GCC and ACC haplotype distribution differed
between TB cases and controls [19].
It is established that distinct IL10 promoter haplotypes correlate
with the transcriptional activity of IL10, whereby high, interme-
diate and low IL-10 production is associated with the IL10
21082/2819/2592 combinations GCC, ACC and ATA,
respectively [20–22]. We hypothesized that IL10 promoter
variants might be involved in the quality of innate immune
responses. Therefore, we assessed the frequencies of four promoter
variants and their significance in HIV-negative TB patients and
compared them with healthy exposed controls in a population
from Ghana, West Africa. Controls were stratified according to
their PPD reactivity and grouped into subgroups of PPD-positive
and PPD-negative participants. This allowed to address innate
immunity to TB by comparisons of cases versus controls, PPD-
positive versus PPD-negative controls, and cases plus PPD-positive
versus PPD-negative controls. Any influence exerted by the IL10
variants on the extent of T-cell responses should be reflected in our
sample of sputum-positive TB cases that we recruited in Ghana
and compared it to a control group of significant size.
Materials and Methods
Ethics Statement
The study protocol was approved by the Committee on Human
Research, Publications and Ethics, School of Medical Sciences,
Kwame Nkrumah University of Science and Technology, Kumasi,
Ghana, and the Ethics Committee of the Ghana Health Service,
Accra, Ghana. Blood samples were taken only after a detailed
explanation of the aims of the study, and consent was obtained by
signature or thumbprint.
Patients and controls
Participants were consecutively enrolled in Ghana, West Africa,
between September 2001 and July 2004 at Korle Bu Teaching
Hospital in Accra, Komfo Anokye Teaching Hospital in Kumasi,
plus 15 additional hospitals and polyclinics in Accra and Kumasi
and at regional district hospitals. The case group included of 2010
HIV-negative individuals with smear-/culture-positive pulmonary
TB. Out of a total of 2346 control individuals, 1211 were
unrelated personal household contacts of cases and 1135 were
individuals from neighbouring houses or working contacts of cases.
Cases and controls belonged to the ethnic groups of Akan
(Ashanti, Fante, Akuapem), Ga-Adangbe, Ewe, all in the south of
Ghana, and several other ethnic groups of northern Ghana. The
proportions of ethnicities among patients and controls are given in
Table 1 and ethnicities were included as a correction factor in all
statistical analyses.
Phenotyping of patients was based on the medical histories and
documentation of major symptoms on structured questionnaires,
physical examination, HIV-1/2 testing (Capillus, Trinity Biotech,
Bray, Co Wicklow, Ireland), posterior-anterior chest X-rays, Ziehl-
Neelsen staining of two independent sputum smears, and culturing
of M. tuberculosis on Loewenstein-Jensen agar with subsequent
determination of mycobacterial species, lineages and fine-typing of
mycobacterial genotypes by spoligotyping, IS6110 and determi-
nation of drug resistances fingerprinting as described previously
[23–25]. Cases were HIV-negative and had lesions characteristic
of pulmonary TB on the chest X-ray films. Patients were treated in
the framework of the DOTS programme (Directly Observed
Treatment Short-Course Strategy) organized by the National
Tuberculosis Programme of Ghana.
Characterisation of controls included a medical history and
clinical examination, chest X-ray and a tuberculin skin test
(Tuberculin Test PPD Me ´rieux, bioMe ´rieux, Nu ¨rtingen, Ger-
many). 2217 individuals were PPD-positive and 129 individuals
were PPD-negative. The group of PPD-negative controls com-
prised, to the large majority, household contacts of cases. The final
group of PPD-negative controls consisted of 129 individuals. The
controls had no radiological signs of actual or previous pulmonary
TB. Further details of the recruitment procedure, the composition
of the study group including the distribution of ethnicities, and
application and interpretation of the PPD test have been described
previously [25–28]. A large subset of the entire study group was
genotyped for IL10 promoter variants in the present study.
Variants selected for genotyping
The selection of IL10 promoter variants for genotyping was
based on the functional relevance with regard to the extent of IL-
10 production of the variant at position 22849 (rs6703630) and
the proximal promoter haplotypes resulting from variability at
positions 21082 (rs1800896), 2819 (rs1800871) and 2592
(rs1800872).
Testing for population stratification
To assess whether population stratification was a major concern
in our study, the median of the Armitage’s trend test statistics of 61
unlinked biallelic markers (see Supplementary Table S1) was
analysed to estimate the inflation factor l for genomic control
[29]. The inflation factor was calculated by dividing the observed
median of the statistics trend tests by the predicted median of the
x
2 statistics of 0.456 if inflation is absent.
Genetic Analysis
After DNA extraction from peripheral blood by a magnetic
separation technology (AGOWAH mag Maxi DNA Iisolation Kit,
Berlin, Germany) according to the manufacturer’s instructions, the
IL10 SNPs 22849, 21082, 2819 and 2592 variants were
analysed by dynamic allele specific hybridization with fluorescence
resonance energy transfer (FRET) in a LightTyper device (Roche
Diagnostics, Mannheim, Germany). Primer pairs and sensor/
anchor oligonucleotides for LightTyper-based IL10 genotyping are
listed in Table 2.
Table 1. Distribution of Ghanaian ethnic groups in TB cases
and controls.
Ethnicity TB cases controls
PPD positive PPD negative
N( % ) N( % ) N( % )
Akan 1279 (63.6) 1292 (58.2) 95 (74.8)
Gaa 292 (14.5) 456 (20.6) 9 (7.1)
Northerners 259 (12.9) 229 (10.3) 16 (12.6)
Ewe 142 (7.1) 214 (9.6) 5 (3.9)
Unknown ethnicity 38 (1.9) 28 (1.3) 2 (1.6)
N, number of individuals. The group of Northeners comprises members of
several ethnicities of Northern Ghana. All statistical analyses were corrected for
ethnicities.
doi:10.1371/journal.pone.0005420.t001
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IL-10 plasma levels of patients homozygous for the IL10
22849/21082/2819/2592 haplotypes GGCC and AACC were
measured by the ‘‘Human IL-10 ELISA Ready-Set-Go’’ kit
(Biocarta, Hamburg, Germany) according to the recommenda-
tions of the manufacturer. The range of detection was between 2
and 300 pg/ml.
Databases and statistical analyses
Demographic data, self-reported signs and symptoms and
primary laboratory results were double-entered into a Fourth
Dimension database (San Jose ´, CA, USA). Microbiological data
were provided as datasheets. All data were locked before using
them in a pseudonymized form for further analyses.
Power calculation was performed with the CATS software
(available at http://www.sph.umich.edu/csg/abecasis/CaTS/).
The STATA 9 software (Stata Corporation, College Station,
TX, USA) with supplementary modules (http://www-gene.cimr.
cam.ac.uk/clayton/software/stata/genassoc) was used to calculate
Hardy Weinberg equilibria (HWE) and odds ratios (OR) of IL-10
genotype frequencies. Logistic regression analyses (STATA 9) were
applied to adjust for gender, age and ethnic groups. Haplotype
frequencies and odds ratios (OR) with global and adjusted P values
(10 000 permutations) were estimated and compared with the
public ‘‘UNPHASED’’ software (version 3.0.12; http://www.
mrc-bsu.cam.ac.uk/personal/frank/software/unphased/).The in-
flation factor for genomic control was calculated using the PLINK
software (version 1.0.5; http://pngu.mgh.harvard.edu/,purcell/
plink/download.shtml).
The nonparametric Mann-Whitney U test (STATA 9 software)
was used to determine differences of IL-10 plasma levels in
individuals homozygous for either the IL-10 22849/21082/
2819 AAC (n=25) or the GGC (n=22) genotype.
Results
Power of the association study; Hardy-Weinberg
equilibrium
A power of detection of .90% was achieved for both additive
and multiplicative models, assuming an approximative TB
prevalence of 0.004 in West Africa, a frequency of 0.1 for high
risk alleles and a genotype relative risk of 1.4 (a=0.001) with our
sample size. The frequencies of the IL10 22849, 21082, 2819
and 2592 variants were tested and adjusted for gender, age and
ethnicity in a large TB case-control sample from Ghana. Genotype
frequencies did not deviate from Hardy-Weinberg equilibrium
among cases and controls with the exception of IL10 22849 in
cases (p=0.02).
Population stratification
The estimated inflation factor for genomic control of l=1.045,
calculated by analysing 61 unlinked genetic markers, did not
reveal a major population stratification in our study group.
IL10 promoter genotypes
Statistical analyses were performed to compare the occurrence
of IL10 promoter genotypes between cases and all controls, cases
and PPD-negative controls, cases and PPD-positive controls and
between the combined group of cases plus PPD-positive controls
and PPD-negative controls. Ethnicities did not influence any
statistical analysis. After adjusting P values for gender, age and
ethnicitiy and correction for multiple testing for the subgroups of
the study population and the four variants tested, genotype
frequencies did not differ significantly between groups (Table 3). A
trend, however, was observed for the IL10 22849AA genotype,
which occurred at higher frequencies among PPD-positive
controls and in the combined groups of cases plus PPD-positive
controls than in PPD-negative controls with an OR of 3.10 (CI
1.1–8.6, nominal P value 0.03), and an OR of 2.84 (CI 1.0–7.8,
nominal P 0.04), respectively. No significant results were obtained
when stratifying TB cases for whom genotyping results were
available (n=1587) for the three mycobacterial species M.
tuberculosis (n=1097; 69.1%), M. africanum (n=480, 30.3%) and
M. bovis (n=10; 0.6%) that were identified after culturing of
mycobacteria (data not shown).
IL10 promoter haplotypes
Reconstruction of haplotypes was performed with the UN-
PHASED software (Table 4). As reference haplotype for
calculations of ORs and 95% confidence intervals (CI), the IL10
haplotype 22849G/21082G/2819C/2592C (GGCC) was cho-
sen, as this haplotype is, most likely, associated with highest
production of IL-10. For the comparisons that yielded significant
global P values and that were stable after corrections for multiple
testing (10 000 permutations calculated with ethnicity included as
a covariate), haplotype-specific ORs were determined. The IL10
haplotype 22849A/21082A/2819C/2592C (AACC), which is
most likely associated with low IL-10 production, was significantly
less frequent in PPD-negative controls than in the group of cases
(9.7% versus 15.5%; OR 2.15, CI [1.3–3.6]). A corresponding
distribution of haplotype frequencies was observed when compar-
ing PPD-negative controls with the combined groups of cases plus
Table 2. Primer pairs and sensor/anchor oligonucleotides for LightTyper-based IL10 genotyping.
IL10 variant rs number primer oligonucleotides sensor/anchor oligonucleotides
IL10 22849 A/G rs6703630 F–TTAGCTACACATTTCAGAACAAATAAAGA S–CCTCCCAGAGTGCTGAGATTACAGGC
R–TTTTTTTTGTATTTTTATTAGAGAGGGGT A–ATGATCCGCCCGCCTTG
IL10 21082 A/G rs1800896 F–ATCCAAGACAACACTACTAAGGC S–CCCTACTTCCCCCTCCCAAA
R–GGGTGGGCTAAATATCCTCAA A-GGATAGGAGGTCCCTTACTTTCCTCTTACC
IL10 2819 C/T rs1800871 F–ATCCAAGACAACACTACTAAGGC S–AGGCACAGAGATATTACATCACCT
R–GGGTGGGCTAAATATCCTCAA A–ACAAGGGTACACCAGTGCTAACTGA
IL10 2592 C/A rs1800872 F–ATCCAAGACAACACTACTAAGGC S–GCTTCCTACAGTACAGGC
R–GGGTGGGCTAAATATCCTCAA A–GGGTCACAGGATGTGTTCCAGGC
F, forward primer; R, reverse primer; S, sensor; A, anchor.
doi:10.1371/journal.pone.0005420.t002
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[1.3–3.5]) and PPD-negative and PPD-positive controls (9.7%
versus 15.3%; OR 2.09, CI [1.2–3.5]). The distribution of
haplotypes in individuals infected with either M. tuberculosis, M.
africanum or M. bovis did not differ when compared to controls and
subgroups of controls.
As estimated haplotype frequencies should not be treated as
observed data and in order to further determine the empirical
significance of our findings, the global P value of differences in
haplotype frequencies was verified by calculating 10 000 permu-
tations. The adjusted and corrected global P values pglobal/corr
remained significant for comparisons of PPD-negative controls
with cases (pglobal/corr=0.013), PPD-negative controls with the
combined group of cases plus PPD-positive controls (pglobal/corr
=0.012) and PPD-negative controls with PPD-positive controls
(pglobal/corr=0.017). The associations held true when including
ethnicity as a covariate.
IL10 plasma levels
In order to confirm that the combination of 22849G and the
haplotype 21082G/2819C/2592C is in fact associated with
higher Il-10 plasma levels, concentrations of IL-10 were
determined in patients homozygous for either GGCC (n=22) or
AACC (n=25) by an enzyme linked immunosorbent assay before
the initiation of antimycobacterial treatment. Significantly higher
plasma levels of IL-10 (p=0.016; Figure 1) could be confirmed to
occur among carriers of GGCC compared to AACC. Mean
plasma levels of GGCC and AACC cariers were 74.4 pg/ml (CI
[56.6–92.2]) and 46.9 pg/ml (CI [35.6–58.1]), respectively.
Discussion
The numerous studies undertaken to identify genetic correlates
of resistance and susceptibility to pulmonary TB have provided
inconsistent evidence of a few candidate genes that exert minor
influences only. In order to ascertain true exposure to M.
tuberculosis, most of the genetic studies conducted so far have
focused on comparisons of cases with PPD-positive controls.
Although a substantial body of immunological in vitro findings
suggests that innate resistance of humans to M. tuberculosis may
occur, it has received by far less attention in genetic association
studies.
Studies of the proximal IL10 21082G/A, 2819C/T, 2592C/
A promoter haplotypes in different populations have shown that,
at these positions, only the haplotypes GCC, ACC and ATA
occur. The few studies reporting on other than these haplotypes in
China and Thailand (ATC, ACA) [30] await confirmation.
Genotyping of the variants at positions 21082 and 2819 allows,
therefore, to include in haplotype reconstruction the variant at
position 2592 [14]. In order to ascertain the preferential
occurrence of these haplotypes in our African study population,
we have genotyped the IL10 2592 nucleotide in a subsample of
our study group (n=2470) and confirmed those haplotypes with
the UNPHASED haplotype estimation algorithm.
It is also established that the three haploytypes differentially
affect the transcriptional activity of the IL10 gene. High,
intermediate and low IL-10 production is associated with the
proximal IL10 promoter combinations GCC, ACC and ATA,
respectively [14,16]. Compared to the IL10 22849GG genotype,
the AA genotype is strongly associated with lower IL-10
production, as is the proximal ATA haplotype [31,32]. The
relevance for IL-10 production of the IL10 22849 variants has, to
our knowledge, not been assessed together with that of the
proximal IL10 21082/2819/2592 haplotypes. Based on the
functional results available so far for the distal IL10 22849 variant
and the proximal haplotypes it was, however, conceivable that the
IL10 22849A/21082A/2819C/2592C (AACC) haplotype that
we observed at higher frequencies among cases and PPD-positive
controls than in PPD-negative controls causes rather low
constitutional IL-10 levels. Significantly higher IL-10 plasma
levels of homozygous carriers of the IL10 GGCC haplotype,
compared to homozygous AACC carriers, were confirmed by the
determination of IL-10 plasma levels in the group of TB patients
(Figure 1). The IL-10 concentrations in plasma that were
measured before the initiation of specific antimycobacterial
treatment were similar to those reported previously [33,34]. The
Figure 1. IL-10 plasma levels (pg/ml) in individuals homozygous for the presumed ‘‘low’’ and ‘‘high producer’’ haplotypes 22849A/
21082A/2819C (AAC) and 22849G/21082G/2819C (GGC). Concentrations differ significantly between AAC and GGC carriers (p=0.016;
Mann-Whitney U test).
doi:10.1371/journal.pone.0005420.g001
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AATA, was observed at lowest frequencies only in our study
population that did not allow further analyses.
The frequencies of the IL10 22849 genotypes were in HWE
among controls, but not among cases. Notably, the frequencies
were in a sample from Ghana and in African-Americans almost
identical to those observed in our study [35,36] and they were
largely similar in a population of European descent [30].
Associations with the IL10 22849 polymorphism or with
haplotypes comprising this variant have also been described in
other conditions, e.g. in rheumatoid arthritis, decreased female
fertility, systemic sclerosis, pre-eclampsia, and in leprosy [37–41].
Our findings indicate that individuals exists who are exposed to
M. tuberculosis infection, but are genetically distinct from both PPD
positives and TB cases. This observation substantiates epidemio-
logical evidence that even heavy exposure to M. tuberculosis of
healthy individuals in closed environments may result in a lack of
tuberculin skin response [5,6]. We have, in our study, included
PPD-negative controls who were exposed to M. tuberculosis
transmission and have observed the greatest difference of
haplotype frequencies in the comparisons of PPD-negative
controls with TB cases and PPD-positive controls. The haplotype
that is, based on the aforementioned functional studies, most likely
associated with low IL-10 production (22849A/21082A/
2819C/2592C; AACC) was less frequent among PPD-negative
controls than among cases and PPD-positive controls, including
the combined groups of cases plus PPD-positive controls,
compared to the reference haplotype GGCC which is associated
with high IL-10 production. Notably, and with respect to the
presumed decreasing extent of IL-10 production of the different
haplotypic combinations given in Table 3, ORs of comparisons of
haplotype frequencies increased gradually from the high-producer
GGCC haplotype to the low-producer haplotype AACC in those
comparisons that provided significant global and corrected P
values (cases vs. PPD-negative controls, PPD-positive vs. PPD-
negative controls, cases plus PPD-positive vs. PPD-negative
controls; Table 3).
The pro-inflammatory response that is initiated by M. tuberculosis
is antagonized by anti-inflammatory mechanisms. After phagocy-
tosis of the pathogen, macrophages, T-lymphocytes and other cells
produce IL-10 [42–44]. Among further determinants involved, the
extent of IL-10 production depends largely on the genetic
composition of the promoter haplotype. The overall consequences
of IL-10-dependent immunological mechanisms are typically dose-
dependent. In an early phase of the infection, IL-10 attenuates
mechanisms that cause activation of adaptive immune effector
cells [45]. At the same time, antigen presentation is impaired by
retarded maturation of antigen presenting cells that are infected
with mycobacteria. Inflammation is confined and the generation
of adaptive immunity is postponed [46]. The effects exerted by IL-
10 may result in antigen-specific anergy [47], which is compatible
with PPD negativity in the present study. Such a state of a delayed
and decelerated development of specific adaptive responses
enhances local effects of innate immune mechanisms that, to a
certain degree, may successfully control a pathogen. When initial
clearance of pathogens by innate immunity fails, inflammation
progresses and T-cell responses develop differentially, resulting in
either PPD positivity or in manifest pathology.
We believe that the lower frequency of the IL10 promoter
haplotype AACC among PPD-negative individuals reflects
functional differences between PPD-positive and PPD-negative
control individuals rather than between cases and PPD-negative
controls. PPD-negativity might result from IL-10-dependent T-cell
suppression, and the actual levels of IL-10 are likely to determine
either T-cell reactivity or anergy. Antigen-specific tuberculin
anergy has been shown to occur in patients during active TB and
persisting even after successful treatment [1,4], and higher IL-10
levels have been documented in these patients when compared to
PPD-positive individuals. Since the cases of our study did not
undergo tuberculin testing, we cannot exclude IL-10-dependent
PPD negativity in a subgroup of our cases. It is conceivable that
the rate of PPD negativity in our case-group corresponds to that of
the total control-group and that haplotype-associated dose-
dependent IL-10 effects in cases and controls may cause either
PPD-negativity or PPD-positivity.
Since the association that we observed does not apply to the
entire study group but only to a subfraction as tuberculin tests
were not performed on cases, the IL10 promoter haplotypes
GGCC and AACC are certainly not surrogate markers for the
assessment of disease risk or the quality and extent of the skin test
response after exposure to M. tuberculosis antigens. However, and
with regard to the sample size and the robustness of case and
control phenotypes, in particular the exposure of PPD-negative
controls to M. tuberculosis, our results make a contribution of IL10
promoter haplotypes to the polygenic mosaic of TB susceptibility
likely. An adjusted equilibrium of pro- and anti-inflammatory
mechanisms exerted by IL-10 appears to depend at least in part on
the individual genetic profile of its promoter.
Supporting Information
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Found at: doi:10.1371/journal.pone.0005420.s001 (0.03 MB
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